Evidence map›Paper›PMID 39959402›Full record

ArticleIJTLD open2025

Use of putative hepatoprotective agents as an adjunct to anti-TB treatment in Europe.

O Kirakosyan, M Reimann, A B Andersen, A Bjarnason, Á Bakos, A M Dyrhol-Riise, A M McLaughlin, C Nita, D Pieridou, D Chesov and 28 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in IJTLD open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. HBV/HCV coinfection and anti-tuberculosis drug-induced liver injury: from risk assessment and exploration of mechanisms to preventive considerations.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2026
    Review
  2. Silymarin Reduces the Inflammatory Response and the Burden ofInternational journal of microbiology · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

38 authors.

O KirakosyanDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
M ReimannDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
A B AndersenOdense University Hospital, Department of Infectious Diseases, Copenhagen, Denmark.
A BjarnasonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Á BakosKoranyi National Institute for Pulmonology, Budapest, Hungary.
A M Dyrhol-RiiseDepartment of Infectious Diseases, Oslo University Hospital, Oslo, Norway.
A M McLaughlinNational TB Centre, St James's Hospital, Dublin, Ireland.
C NitaMarius Nasta National Center of Pneumology, Bucharest, Romania.
D PieridouNational Reference Laboratory for Mycobacteria, Nicosia General Hospital, Nicosia, Cyprus.
D ChesovDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
E V DavidavičienėVilnius University Hospital Santaros Klinikos, Department of Tuberculosis State Information System, Vilnius, Lithuania.
G GüntherDepartment of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
H AtshemyanNational Center of Pulmonology, Yerevan, Armenia.
I MuylleDivision of Pneumology, Onze-Lieve-Vrouw Ziekenhuis (OLV) Aalst, Aalst, Belgium.
I SolovicNational Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia.
J BruchfeldUnit of Infectious Diseases, Department of Medicine, Karolinska Institute, Stockholm, Sweden.
K ManikaRespiratory Diseases and Tuberculosis Pulmonary Department, Aristotle University of Thessaloniki, "G. Papanikolaou" Hospital, Thessaloniki, Greece.
L KuksaRiga East University Hospital, Tuberculosis and Lung Disease Clinic, WHO CC, Riga, Latvia.
L R CodecasaRegional TB Reference Centre, Villa Marelli Institute-Niguarda Hospital, Milan, Italy.
M StosicInstitute of Public Health of Serbia "Dr Milan Jovanovic Batut", Belgrade, Serbia.
M SkowrońskiTuberculosis Department, Wielkopolskie Center of Pulmonology and Thoracic Surgery, Poznań, Poland.
M J MakekUniversity of Zagreb, School of Medicine, Zagreb, Croatia.
M Fréchet JachymCentre Hospitalier de Bligny, Briis-sous-Forges, France.
M KnappikKlinik Penzing, Vienna, Austria.
M SantinTuberculosis Unit, Department of Infectious Diseases, Bellvitge University Hospital-Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, Barcelona, Spain.
N YatskevichThe Republican Scientific and Practical Center for Pulmonology and Tuberculosis, Minsk, Belarus.
O KonstantynovskaV. N. Karazin Kharkiv National University, Department of Infectious Diseases and Clinical Immunology, Kharkiv, Ukraine.
O AkkermanUniversity of Groningen, University Medical Centrum Groningen, Dept of Pulmonary Diseases and Tuberculosis, Groningen, The Netherlands.
P SvetinaNational TB Program and Tuberculosis Registry of Republic of Slovenia, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia.
P ViikleppNational Institute for Health Development, Tallinn, Estonia.
R DuarteUnidade de Investigação em Epidemiologia (EPI Unit), Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal.
S ZeynelInstitute for Lung Diseases and Tuberculosis, Skopje, North Macedonia.
T TogonidzeNational Center for Tuberculosis and Lung Diseases, Tbilisi, Georgia.
T VasankariFinnish Lung Health Association (Filha), Helsinki, Finland.
V ParrisLondon North West University Healthcare NHS Trust, London, UK.
Ş ÖzkaraAtatürk Chest Diseases and Chest Surgery Education and Research Hospital, 8th Clinic, Sanatoryum Caddesi, Ankara, Turkey.
C LangeDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.
T T BrehmDepartment of Clinical Infectious Diseases, Research Center Borstel, Leibniz Lung Center, Borstel, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnecdotal information suggests that clinical practice regarding the use of putative hepatoprotective agents in TB treatment varies across countries in the WHO European Region.

methodsBetween November 2023 and May 2024, we conducted a standardised questionnaire survey on the use of putative hepatoprotective agents in patients receiving TB treatment among Tuberculosis Network European Trials Group (TBnet) representatives in countries in the WHO European Region.

resultsWe received valid responses from 37 of 53 countries (69.8%), with 16 (43.2%) reporting regular use of putative hepatoprotective agents during anti-TB treatment. Half of these countries (

conclusionsPutative hepatoprotective agents are widely used as an adjunct to TB treatment in the WHO European Region, particularly in the countries of the former Soviet Union, some of which have included them in their national guidelines.

Indexed as

drug-induced liver injuryhepatitishepatotoxicitysilibininursodeoxycholic acid

Identifiers

PMID39959402
PMCPMC11827669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.